Key facts
- Longevity AI’s last known valuation is $13.0M (May 2025).
- It has raised $5.2M; the latest was Early Stage VC ($4.5M) in May 2025.
- Notable investors include Kli Capital, Welltech Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Longevity AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Longevity AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Longevity AI
Developer of a preventive healthcare platform designed to offer early diagnosis and intervention of major age-related diseases. The company's platform utilizes artificial intelligence to offer a clinical dashboard for an understanding of patients, makes risk predictions based on the latest scientific discoveries, evidence-based medicine, and health information, provides health reports after every visit, and offers insights into habits and preferences, along with smart monitoring, enabling health providers to treat patients efficiently and improve the experience.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2021
- Employees
- 32
- Website
- longevity-ai.com/
- Ownership
- Privately Held (backing)
Longevity AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Longevity AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Longevity AI in its N-PORT filings yet. We sweep new filings monthly.